<header id=008467>
Published Date: 2021-07-30 18:38:08 EDT
Subject: PRO/AH/EDR> COVID-19 update (262): Pfizer effect., MIS-C, Israel breakthroughs/boosters, WHO
Archive Number: 20210730.8557829
</header>
<body id=008467>
CORONAVIRUS DISEASE 2019 UPDATE (262): PFIZER EFFECTIVENESS, MIS-C IN CHILDREN, ISRAEL BREAKTHROUGH INFECTIONS, BOOSTERS, WHO
*****************************************************************************************************************************
A ProMED-mail post
http://www.promedmail.org
ProMED-mail is a program of the
International Society for Infectious Diseases
http://www.isid.org

In this update:
[1] Pfizer effectiveness
[2] MIS-C in children
[3] Israel: breakthrough infections
[4] Israel vaccine advisory group: boosters
[5] WHO: daily new cases reported (as of 29 Jul 2021)
[6] Global update: Worldometer accessed 29 Jul 2021 20:59 EST (GMT-5)

******
[1] News scan: Pfizer effectiveness
Date: Thu 29 Jul 2021
Source: CIDRAP (Center for Infectious Disease Research and Policy) [edited)
https://www.cidrap.umn.edu/news-perspective/2021/07/news-scan-jul-29-2021


Vaccine effectiveness (VE) for the Pfizer/BioNTech COVID-19 vaccine against COVID-19 was 91% up to 6 months after the 2nd dose, according to a non-peer-reviewed study published yesterday [28 Jul 2021] on the preprint server medRxiv [see citation below].

The researchers followed 44 060 people 16 and older, randomly assigning half to receive 2 doses of the Pfizer/BioNTech vaccine and half to a placebo. Most of the 152 recruitment sites were in the United States (130), followed by Turkey (9), Germany (6), and South Africa (4). The study also followed 2260 US children 12-15 years old, with half receiving the intervention and half receiving placebo.

VE was 91.1% up to 6 months after the 2nd vaccine dose, regardless of previous COVID-19 infection (95% confidence interval [CI], 89.0 to 93.2). Against severe disease it was 97% (95% CI, 80.3% to 99.9%).

When the researchers looked at VE across age, sex, race, or COVID-19 risk factors, VE was always 86% or higher, although they note that youth data was not available for 6 months because of when enrollment began (15 Oct 2020, vs 27 Jul 2020, for adults). VE peaked at 96.2% from 7 days to less than 2 months after the 2nd dose, but at 4 months it declined to 83.7%, with an average decline of 6% every 2 months.

More vaccine recipients reported local and systemic events than placebo recipients, with mild-to-moderate injection-site pain and fatigue being the most common, respectively. People who had COVID-19 prior to vaccination reported more systemic reactions after the 1st dose, whereas those who were naive to COVID-19 reported more systemic reactions after the 2nd. While 15 vaccine recipients and 14 placebo recipients died, none of the deaths were considered related to the intervention.

Because reactogenicity events among participants not in the reactogenicity subset were reported as adverse events, the researchers say that the data show imbalances toward the Pfizer group (30% vs 14% for adverse events, 24% vs 6% for related adverse events, and 1.2% vs 0.7% for severe adverse events).

"Despite a gradually declining trend in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing COVID-19," the researchers conclude.

--
Communicated by:
Mary Marshall
<mjm2020@googlemail.com>

[The citation of the article referenced above follows:
Thomas SJ, Moreira Jr. ED, Kitchin N, et al. Six-month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv. 2021; https://doi.org/10.1101/2021.07.28.21261159.]

******
[2] MIS-C in children
Date: Thu 29 Jul 2021
Source: CIDRAP (Center for Infectious Disease Research and Policy) [edited]
https://www.cidrap.umn.edu/news-perspective/2021/07/news-scan-jul-29-2021


In a longitudinal cohort of 25 children with multisystem inflammatory syndrome in children (MIS-C), all were asymptomatic and at their functional baseline at 6-month follow-up, according to a Pediatrics study yesterday [28 Jul 2021] [see citation below]. The study included a total of 50 children, with some lost to follow-up, but during all intermediary follow-ups, symptoms were improving.

All study participants were admitted to Cohen Children's Medical Center with MIS-C from 17 Apr-20 Jun 2020 (median age, 8.5 years; range, 9 months-17 years). Most patients exhibited rapid clinical improvement, with an average hospital stay of 5 days. At discharge, 69% of 26 patients with left ventricular (LV) systolic dysfunction had resumed normal function, 15% had persistent but improved dysfunction, and 15% had mild dysfunction at admission but no available discharge data.

At 2 weeks, 47 presented for follow-up, and 47% said they got tired with ordinary activities, most of whom (81.8%) experienced shock or myocardial systolic dysfunction at initial admission. All other patients were asymptomatic. Platelet levels were elevated compared with admission (median, 463 000 cells per microliter vs 172 000), but all other markers had normalized. Some LV systolic (one patient) and diastolic (5) function persisted.

The follow-up at 8 weeks involved 42 people, with 5 (12%) continuing to experience fatigue during regular activity. All LV systolic function was normal, and any remaining coronary aneurysms and dilation had resolved. However, 4 (9%) still had diastolic dysfunction, and 5 (12%) had qualitative coronary abnormalities.

By 6 months, the 25 available patients were asymptomatic and at their functional baselines. Despite being asymptomatic, one patient still had LV diastolic dysfunction, but cardiac magnetic resonance imaging at 8 weeks didn't show inflammation or fibrosis.

"Early and mid-term prognosis after hospitalization and immunomodulation treatment for MIS-C is excellent with return to functional baseline, normalized LV systolic function, and resolved coronary abnormalities. However, persistence of diastolic dysfunction in a few patients confounds our understanding of MIS-C," write the researchers.

--
Communicated by:
Mary Marshall
<mjm2020@googlemail.com>

[The citation of the article referenced above follows:
Capone CA, Misra N, Ganigara M, et al. Six-month follow-up of patients with multisystem inflammatory syndrome in children. Pediatrics. 2021; <doi: 10.1542/peds.2021- 050973>.]

******
[3] Israel: breakthrough infections
Date: Thu 29 Jul 2021
Source: CIDRAP (Center for Infectious Disease Research and Policy) [edited]
https://www.cidrap.umn.edu/news-perspective/2021/07/israeli-study-finds-26-covid-breakthrough-infection-rate-0


A New England Journal of Medicine study yesterday [28 Jul 2021] details breakthrough COVID-19 infections in 39 of 1497 fully vaccinated Israeli healthcare workers, with most cases mild or moderate, but 19% with symptoms lingering for more than 6 weeks [see citation below].

A team led by Tel Aviv University researchers used diagnostic testing, antibody assays, genomic sequencing, and contact tracing to evaluate healthcare workers who were symptomatic or had been exposed to an infected person.

All workers had received a 2nd dose of the Pfizer/BioNTech vaccine 11 days before the study began on 20 Jan [2021]. The study ran for 14 weeks, during which time Israel experienced its 3rd and largest COVID-19 case surge.

The researchers also matched workers with COVID-19 and antibody concentrations obtained within a week before diagnosis with 4 or 5 uninfected controls and used generalized estimating equations to predict average antibody levels and the ratio between the levels in the 2 groups.

In total, 2.6% of the healthcare workers had breakthrough COVID-19 infections, 67% of which were mild and 33% of which were asymptomatic. The most common symptoms were upper respiratory congestion (36%), muscle pain (28%), loss of smell or taste (28%), and fever or chills (21%).

"In this study, we found that although the [Pfizer] vaccine is extremely effective, rare breakthrough infections carry an infectious potential and create a special challenge, since such infections are often asymptomatic and may pose a risk to vulnerable populations," the researchers wrote.

[A total of] 31% of infected workers reported persistent symptoms 14 days after their diagnosis, and 19% reported "long COVID" symptoms of loss of smell, cough, fatigue, weakness, shortness of breath, or muscle pain for more than 6 weeks. None were hospitalized. Of the 23% of workers who took a leave of absence from work for more than the mandatory 10-day quarantine, 4 returned to work within 2 weeks, and one still hadn't returned after 6 weeks.

The alpha (B117) SARS-CoV-2 variant, which was dominant in Israel at the time, was identified in 85% of tested samples. Of all workers, 74% had a high viral load (cycle threshold [Ct] value less than 30) at some point during their illness, suggesting contagiousness. No secondary infections were identified, which the researchers said suggests that the infected workers were less contagious than their unvaccinated peers.

The workers had lower neutralizing antibody levels in the week before diagnosis (peri-infection period) than did matched controls (case-to-control ratio, 0.361). Higher antibody levels were linked with lower infectivity (higher cycle threshold values).

"Among fully vaccinated healthcare workers, the occurrence of breakthrough infections with SARS-CoV-2 was correlated with neutralizing antibody titers during the peri-infection period," the authors wrote.

The likely source of COVID-19 infection in all 37 healthcare workers with available data was an unvaccinated person, which was a household member in 57% of the cases. In 30% of cases, the suspected source was an unvaccinated fellow healthcare worker or patient, of which 7 of 11 were linked to a single hospital outbreak involving an unvaccinated index patient who had been receiving noninvasive positive-pressure ventilation before being diagnosed as having the alpha variant.

Of the total cohort, 46% were nursing staff members, 26% worked in administration or maintenance, 15% were allied health professionals, and 13% were physicians. Average age was 42 years, 64% were women, and only one person was immunosuppressed. The median interval between the 2nd vaccine dose and COVID-19 diagnosis was 39 days.

The authors said that the results are important to predicting how the expected decay of SARS-CoV-2 antibody levels after vaccination will affect clinical COVID-19 outcomes, whether a booster dose will be needed, and whether vaccinated people are protected. "Such capacity for prediction is particularly important for new vaccine development," they wrote.

[Byline: Mary Van Beusekom]

--
Communicated by:
Mary Marshall
<mjm2020@googlemail.com>

[The citation of the article referenced above follows:
Bergwerk M, Gonen T, Lustig Y, et al. COVID-19 breakthrough infections in vaccinated health-care workers. NEJM. 28 Jul 2021; doi: 10.1056/NEJMoa2109072.]

["With delta, almost everyone who dies from COVID-19 -- 99.5% of known cases -- are unvaccinated people, along with 97% of people hospitalized for the illness. That suggests that the vaccines are still highly effective, said US Surgeon General Dr. Vivek Murthy during a recent press briefing."

"In the US, no one knows exactly how many breakthrough cases there really are because nationwide data doesn't exist. The agency [the CDC] does not count vaccinated people who have been diagnosed with the disease but are asymptomatic or have only mild symptoms, said Dr. Ashish Jha, dean of Brown University's School of Public Health. That's problematic, he said, because the way researchers count infections among vaccinated people is vital to investigating this continually evolving virus, he said.

"'One of the most critical questions is how much forward-transmission is happening from breakthrough infections,' Jha said. 'That's something I don't feel like we have a good grip on and is absolutely essential to understand.'

"These are really important questions, and it is really difficult to answer them without data, Wen said, who added that, 'we need to understand what we're dealing with here.'

"The risk of a breakthrough infection for vaccinated people with symptoms upon exposure to the delta variant is reduced by 7-fold, and that reduction is 20-fold for hospitalizations and death, Dr. Rochelle Walensky, who directs the CDC, said Tuesday [27 Jul 2021].

"However, the CDC does track cohorts of fully vaccinated essential workers, including those in the health-care and long-term-care industries, to better understand how protective vaccines are. Dr. Anthony Fauci, the White House's chief medical advisor, told PBS NewsHour anchor Judy Woodruff on Tuesday [27 Jul 2021] that, from those cohorts, they are seeing data showing that fully vaccinated people who get infected 'clearly can transmit it to other people.'"
(https://www.pbs.org/newshour/health/breakthrough-covid-infections-show-the-unvaccinated-are-now-putting-the-vaccinated-at-risk) - Mod.LK]

******
[4] Israel vaccine advisory group: boosters
Date: Thu 29 Jul 2021
Source: CIDRAP (Center for Infectious Disease Research and Policy) [edited]
https://www.cidrap.umn.edu/news-perspective/2021/07/israeli-advisors-back-covid-vaccine-boosters-older-people


Israel's vaccine advisory group today [29 Jul 2021] recommended that adults in older age groups receive a booster COVID dose, a strategy that other countries are eyeing as delta (B1617.2) variant activity surges and questions swirl about the length of vaccine protection.

Many global health experts have criticized countries for considering booster doses, given that health workers and at-risk groups in many low- and middle-income countries have not received their 1st doses and that the science isn't clear about the need for the boosters. Meanwhile, African officials today said vaccine deliveries are improving.

In Israel, the health ministry's vaccine advisory group recommended a booster dose for older adults but was divided on whether the cutoff should be 60, 65, or 70, according to Haaretz, a newspaper based in Tel Aviv [https://www.haaretz.com/israel-news/israeli-health-ministry-panel-recommends-third-covid-shot-for-older-people-1.10049085].

Data presented at the group's meeting suggested that the vaccine's effectiveness against severe disease in 60-year-old people has declined from 97% in January [2021] to 81%. Israel is using 2-dose mRNA vaccines in its immunization program.

Most of the panel members agreed that people age 60 and older should receive a booster, but some pushed for an older limit. The head of the country's health ministry is expected to make the final decision, and government leaders will discuss the health and economic factors of adding a 3rd dose.

At the end of June [2021], the UK's Joint Committee on Vaccination and Immunization (JCVI) issued interim recommendations for a booster dose, which said any potential booster dose program should begin in September [2021] to head off extra pressure on health systems if SARS-CoV-2 circulates alongside seasonal flu.

They said any potential booster shot program should be rolled out in 2 stages: 1st in those older than 70 and in high-risk groups such as health workers and those who are immunocompromised, then 2nd in all adults older than 50 and those who are in other risk groups.

Africa patterns show a mixed picture, with more vaccine on the way
------------------------------------------
At a media briefing today [29 Jul 2021], the head of the WHO's African region office said Africa is still in the middle of its 3rd wave, but cases have declined for 2 weeks in a row. Matshidiso Moeti, MBBS, said the slight slowdown is promising and a cause for cautious optimism. "But we are not out of the woods yet" [https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-interim-advice-potential-covid-19-booster-vaccine-programme-winter-2021-to-2022].

She said most of the drop this week was in South Africa, the region's hardest hit country. However, 22 countries in Africa reported steep rises of 20% or more over the past 2 weeks, with the highly transmissible delta variant now detected in 26 of the region's countries.

Regarding vaccine supply, Moeti said supplies are quickly ramping up from multiple sources, after stalling in June [2021]. Africa received 4 million doses from COVAX last week, with deliveries from the African Union's procurement program also picking up. The United States announced yesterday [28 Jul 2021] that it was donating 5.7 million doses of Pfizer vaccine to South Africa through the COVAX program.

So far, only 1.6% of the continent's population is fully vaccinated, 61 times less than high-income countries. "There's light at the end of the tunnel on vaccine deliveries to Africa, but it must not be snuffed out again. I urge all countries with surplus doses to urgently share more in the spirit of life-saving solidarity and enlightened self-interest, because no country is safe until all countries are safe," she said, adding that African countries should step up their preparedness to receive and deploy the incoming doses.

More global headlines
--------------------
- In an address to the United Nations General Assembly yesterday [28 Jul 2021], the 2 experts who led the independent panel that reviewed the world's response to the pandemic and issued recommendations in May [2021] said the pandemic is an ongoing disaster that could have been averted. Ellen Johnson Sirleaf, Liberia's former president, and Helen Clark, New Zealand's former prime minister, said geopolitical tensions and nationalism have weakened the multilateral system to keep the world safe. They called on the General Assembly to do more to back reforms and strengthen the world's system for handling pandemic threats.
- China's cases are at a 6-month high in the wake of an outbreak in Nanjing involving the delta variant that has spread to 13 cities and 7 provinces, according to the Washington Post [<wapo.st/3fhrQVQ>]. Also, Beijing has reported its 1st case in nearly 6 months, according to CNN [<cnn.it/3fhrVZE>].
- In other Asian developments, Tokyo's cases reached another daily high, with 3865 new infections in the city that is currently hosting the Olympic summer games. Thailand reported another single-day high, amid reports of hospitals in Bangkok running out of beds, and Myanmar's junta government has asked for outside help in battling its surge.
- In the Middle East, the delta variant is fueling surges in a number of countries and has now been reported in 15 of the 22 nations, the WHO's Eastern Mediterranean office said today [29 Jul 2021]. The hardest hit countries so far include Iran, Iraq, Tunisia, and Libya, where some hospitals are reaching capacity and oxygen supplies are in short supply.
- In Australia's New South Wales state, where the greater Sydney area is battling an outbreak, officials reported another daily record high, amid a report that the country has asked the military to help enforce the city's lockdown, which was recently extended by 4 weeks.
- The global total today [29 Jul 2021] topped 196 million cases and is at 196 077 698 cases with at least 4 187 339 deaths, according to the New York Times [https://www.nytimes.com/interactive/2021/world/covid-cases.html].

[Byline: Lisa Schnirring]

--
Communicated by:
Mary Marshall
<mjm2020@googlemail.com>

[There is disagreement over administration of a booster dose. Pfizer, which advocates the booster, cites the Israeli data above. Furthermore, "among people ages 65 to 85, the Pfizer data suggest that antibody levels that should protect against delta, grow 11-fold more than following a 2nd dose.

"The data, which involved tests of 23 people, have not yet been peer-reviewed or published.

"It's not clear if boosted antibody levels actually correlate to better protection, or if that extra protection is even needed. The US Centers for Disease Control and Prevention says the current vaccines protect people well against all the common variants" [https://www.cnn.com/2021/07/28/health/pfizer-third-dose-data-bn/index.html].

"Pfizer and partner BioNtech released new safety and efficacy data for their coronavirus vaccine Wednesday [28 Jul 2021] and said it shows that protection holds up for at least 6 months, although it may start to wane slightly toward the end of that time.

"The pre-print paper [see citation below], posted Wednesday [28 Jul 2021] to the online server <medrxiv.org>, updates results from Pfizer's trial involving 44 000 volunteers around the world" [https://www.cnn.com/2021/07/28/health/pfizer-third-dose-data-bn/index.html]."

In addition to the debate over necessity of a booster dose, there is the issue that when frontline workers in less developed countries have not yet been vaccinated with their 1st dose, is it ethical to begin booster doses in the developed world? This inequity comes up repeatedly. - Mod.LK]

The citation of the article referenced above follows:
Thomas SJ, Moreira Jr. ED, Kitchin N, et al. Six-month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv. 2021; https://doi.org/10.1101/2021.07.28.21261159.]

******
[5] WHO: Daily new cases reported (as of 29 Jul 2021)
Date: Thur 29 Jul 2021
Source: WHO [abridged, edited]
https://covid19.who.int/table

*Daily case reports as of 29 Jul 2021 16:48 CET

Surveillance
------------
WHO region (no. countries/territories):
Total confirmed cases (new cases in last 24 hours) / Total deaths (new deaths in last 24 hours)
--------------------------------------------------------------------------------
Western Pacific Region (19): 4 374 055 (43 474) / 63 299 (383)
European Region (61): 59 638 715 (128 065) / 1 216 192 (445)
South East Asia Region (10): 38 018 705 (127 662) / 560 839 (3295)
Eastern Mediterranean Region (22): 12 401 911 (71 680) / 233 675 (587)
Region of the Americas (54): 76 584 467 (192 694) / 1 999 953 (3267)
African Region (49): 4 868 312 (31 574) / 115 177 (827)
Cases on an international conveyance (Diamond Princess): 745 (0) / 13 (0)

Confirmed cases (new cases in last 24 hours) / Total deaths (new deaths in last 24 hours)
Grand total: 195 886 929 (595 149) / 4 189 148 (8804)

--
Communicated by:
ProMED
<promed@promedmail.org>

[Data by country, area, or territory for 28 Jul 2021 can be accessed at <bit.ly/2Vqdtru>

- The Americas region reported 32.2% of daily case numbers and 37.1% of the daily deaths reported in the past 24 hours and maintained its position as the most severely affected region, having reported more than 76.58 million cases. The USA reported over 82 000 cases over the last 24 hours followed by Brazil (41 411), Mexico (17 408), Argentina (16 757), and Colombia (11 426). 6 additional countries reported more than 1000 cases in the past 24 hours, while 4 countries reported more than 500 but fewer than 1000 cases.

- The European region reported 21.5% of daily case numbers and 5.0% of the daily deaths reported in the past 24 hours, and total cumulative cases reported exceed 59.63 million cases. Many countries not reporting cases in the last 24 hours or longer include Russia, Belgium (1 case), and Kazakhstan, among others. 9 countries reported more than 1000 cases in the past 24 hours, and an additional 7 countries reported more than 500 but fewer than 1000 cases.

- The Eastern Mediterranean region reported 12.0% of daily case numbers and 6.6% of the deaths reported in the past 24 hours, having reported a cumulative total of more than 12.40 million cases. Iran reported the highest number of cases (33 817) over the last 24 hours, followed by Iraq, Morocco, Pakistan, Saudi Arabia, Libya, Lebanon, and Jordan. Kuwait, and and Oman, reported more UAE,than 500 but fewer than 1000 cases.

- The African region reported 5.3% of daily case numbers and 9.3% of the deaths reported in the past 24 hours, having reported a cumulative total of more than 4.86 million cases. South Africa (17 302), reported the highest number of cases over last 24 hours followed by Mozambique, Algeria, Zimbabwe, and Kenya. Nigeria, Malawi, Rwanda, Eswatini, and Senegal, reported more than 500 but fewer than 1000 cases. Cameroon, Botswana, RÃ©union, Congo, and Seychelles, among others, did not report any new cases in the past 24 hours.

- The Western Pacific region reported 7.3% of daily case numbers and 4.3% of the deaths reported in the past 24 hours, having reported a cumulative total of more than 4.37 million cases. Malaysia, reported the highest number of cases over the last 24 hours (over 17 000 cases), followed by Japan, Vietnam, Philippines, South Korea, Mongolia, Fiji, and Cambodia.

- The South East Asia region reported 21.4% of the daily newly reported cases and 37.4% of reported deaths in the past 24 hours, having reported a cumulative total of more than 38.01 million cases. India is dominant reporting over 43 000 cases over the last 24 hours, followed by Indonesia (43 479), Thailand (17 669), Bangladesh (15 271), Myanmar (5234), and Nepal (335). Additionally, Sri Lanka and Maldives have not reported any cases in the last many days.

On the Overview tab at the WHO source URL, the epidemic curve of confirmed COVID-19 cases by WHO region, 30 Dec 2019 through 29 Jul 2021, is an excellent visual representation of the pandemic. - Mod.UBA]

******
[6] Global update: Worldometer accessed 29 Jul 2021 20:59 EST (GMT-5)
Date: Thu 29 Jul 2021
Source: Worldometer [edited]
https://www.worldometers.info/coronavirus/#countries

[For those who wish to see the detailed global data, a snapshot of the Worldometer table at the time we accessed it is available at https://promedmail.org/wp-content/uploads/world-pdf/2021%20WORLDDATA%20JULY29_1627674959.pdf.

A 7-day series of cumulative data reported by countries, territories, and reporting entities can be found at https://promedmail.org/wp-content/uploads/world-pdf/2021%20JULY29WORLD7_1627674974.pdf. - Mod.UBA]

Total number of reported deaths: 4 214 601
Total number of worldwide cases: 197 364 593
Number of newly confirmed cases in the past 24 hours: 730 286

--
Communicated by:
ProMED
<promed@promedmail.org>

[In the past 24 hours, 17 countries including the USA (92 485), India (44 673), Indonesia (43 479), Brazil (41 852), Iran (34 433), UK (30 980), Spain (26 689), France (25 190), Russia (23 270), Turkey (22 161), Mexico (19 028), Thailand (17 669), Malaysia (17 170), Bangladesh (15 271), Argentina (14 115), South Africa (13 626), and Iraq (13 259), and have reported the highest numbers of cases, all reporting more than 10 000 newly confirmed cases in the past 24 hours. A global total of 10 919 deaths were reported in the past 24 hours (late 27 Jul 2021 to late 28 Jul 2021). A total of 56 countries reported more than 1000 cases in the past 24 hours; 27 of the 56 countries are from the European region, 7 are from the Americas region, 6 are from the Eastern Mediterranean region, 5 are from the South East Asia region, 6 are from the Western Pacific region, and 5 from the African region.

Comparing the 7-day averages of daily confirmed cases from the past 7 days and those from 8-14 days ago, case counts have increased by 5.9%, while daily reported deaths have increased by 0.8%. Similar comparative 7-day averages in the USA show 61.4% increase in daily reported cases and 7.7% decrease in reported deaths.

Impression: The global daily reported over 650 000 newly confirmed infections in the past 24 hours with over 197.36 million cumulative reported cases and over 4.21 million reported deaths. - Mod.UBA]
See Also
COVID-19 update (261): Singapore, mental illness, vaccine mix & match, WHO 20210729.8554984
COVID-19 update (258): CDC mask policy, IDSA, Japan, WHO, global 20210728.8551757
COVID-19 update (256): masks, Promed-ESP, mRNA vaccine 2nd dose, WHO 20210727.8549125
COVID-19 update (255): Indonesia medic. fatal. & variants, nasal involv., WHO 20210726.8546570
COVID-19 update (253): child vaccines, immunocompromised, Europe restrict., WHO 20210725.8544147
COVID-19 update (252): lambda variant, South Asia, Viet Nam, malnutrition, WHO 20210724.8542486
COVID-19 update (251): USA delta variant, Israel vaccines, Olympics, WHO, global 20210723.8540650
COVID-19 update (250): caregiver loss, school buses, mRNA vaccines, WHO 20210722.8538296
COVID-19 update (249): T cell response, GAO, UK, vaccination USA & France, WHO 20210721.8535478
COVID-19 update (248): immunity and variants, vaccines, azithromycin, WHO 20210720.8532784
COVID-19 update (246): Indonesia, France, Germany, Israel, Olympics, WHO 20210719.8530178
COVID-19 update (245): UK, Israel, mask trial retraction, Eurosurveillance, WHO 20210718.8527924
COVID-19 update (244): lambda var S America, long COVID & children, Europe, WHO 20210717.8526331
COVID-19 update (243): Olympics, Africa, MIS-C possible causes, WHO, global 20210717.8524248
COVID-19 update (242): inc. cases and deaths, hosp resources, infec. rates, WHO 20210715.8521711
COVID-19 update (241): South Africa, beta variant, vaccines, Netherlands, WHO 20210714.8518836
COVID-19 update (240): Delta, long Covid, vaccine boosters, Guillian-Barre, WHO 20210713.8516206
COVID-19 update (239): Belgium, vacc. passp., Israel, Russia, Aust., Africa, WHO 20210712.8513581
COVID-19 update (238): missed 2nd vaccinations, future, WHO, global 20210711.8511079
COVID-19 update (237): diagnostics with LFDs, COVID in youth, WHO, global 20210710.8509482
COVID-19 update (236): Africa, Asia, research, WHO, global 20210709.8507651
COVID-19 update (235): CIDRAP, severe, long COVID, gender, schools, WHO 20210708.8505035
COVID-19 update (234): USA Delta var, mAb, Indonesia, long COVID & children, WHO 20210707.8502280
COVID-19 update (232): South Africa, USA delta var., India, Israel, WHO, global 20210706.8499538
COVID-19 update (231): delta variant growth, Olympics, Cuba, global 20210705.8497065
COVID-19 update (229): Lambda variant, diagnostics, prisons, CIDRAP, global 20210704.8495092
COVID-19 update (228): USA vacc, SE Asia surge, evolution, gender disparity, WHO 20210703.8493455
COVID-19 update (227): Delta variant Europe, Africa, Novavax, WHO, global 20210702.8492093
COVID-19 update (226): Bangladesh, mucormycosis, immune response research, WHO 20210701.8489413
COVID-19 update (224): pollen & spread, Indonesia, CIDRAP, sport events, WHO 20210630.8486852
COVID-19 update (223): US hosp. cases (2020), long immunity, Japan Olympics, WHO 20210629.8484172
COVID-19 update (222): Russia, delta variant, US, Afghanistan, WHO 20210628.8481309
COVID-19 update (221): Indonesia, face masks, Australia, WHO 20210627.8478902
COVID-19 update (219): USA, life expectancy, Africa 3rd wave, WHO, global 20210627.8477276
COVID-19 update (218): Russia, vaccine booster, Israel, WHO, global 20210625.8475268
COVID-19 update (217): cognitive, Delta plus variants, immunity, WHO, global 20210624.8473098
COVID-19 update (216): Delta, Delta plus variants, Chinese vaccines, WHO, global 20210623.8469890
COVID-19 update (215): G7 Summit Super spreader, Brazil, Updates, WHO 20210622.8466954
COVID-19 update (214): Brazil, canine CoV, South America, Israel, UK, WHO 20210621.8464589
COVID-19 update (213): Japan, endemic, Afghanistan, cardiac, Lambda variant, WHO 20210620.8462089
COVID-19 update (212): Russia, IDSA, reinfection, Guillain-Barre, regional, WHO 20210619.8460360
COVID-19 update (211): delta variant UK, Indonesia, antiviral pill, WHO, global 20210618.8458589
COVID-19 update (210): mucormycosis, Delta var US, quarantine transmission, WHO 20210617.8456074
COVID-19 update (200): animal, China, origin 20210608.8433657
COVID-19 update (190): Viet Nam, Thailand, UK, vaccine carditis, WHO 20210601.8412653
COVID-19 update (180): variant vaccine, efficacy, Nepal, Southeast Asia, WHO 20210523.8377232
COVID-19 update (170): candidate animal models, potential hosts, research 20210515.8362876
COVID-19 update (160): variants, research, India, WHO 20210505.8346370
COVID-19 update (150): Nepal, India support, Qatar, Japan updates, WHO, global 20210427.8331945
COVID-19 update (140): animal, Latvia, mink, OIE 20210419.8314796
COVID-19 update (130): antibody evasion, variants, South Asia, WHO, global 20210410.8300187
COVID-19 update (120): animal, Russia, vaccine 20210331.8281241
COVID-19 update (110): vaccines, neutralizing antibody, P1 variant, WHO, global 20210323.8263780
COVID-19 update (100): antibodies, vaccine, Thailand, Cambodia, WHO, global 20210316.8250009
COVID-19 update (90): UK sewage, Viet Nam, Cambodia, WHO 20210308.8233859
COVID-19 update (80): vaccine, USA variants, comments, WHO, global 20210226.8214650
COVID-19 update (70): gangrene, challenge trials, immunity, cancer, WHO, global 20210218.8198620
COVID-19 update (60): animal, SARS-CoV-2-related viruses, pangolin, bat 20210211.8184900
COVID-19 update (50): UK vaccine study, Brazil reinfection, WHO 20210205.8167161
COVID-19 update (01): variants, vaccine, Thailand, global, WHO 20210101.80629382020
2020
----
Undiagnosed pediatric inflammatory syndrome (06): COVID-19, heart, young adults 20200522.7364506
COVID-19 update (562): viral load, UK vacc dose, ECDC, WHO 20201231.8061525
COVID-19 update (01): China, global, EVZD, reporting criteria, WHO 20200213.6984084
Novel coronavirus (42): China, global, COVID-19, SARS-CoV-2, WHO 20200211.6979942
Novel coronavirus (01): China (HU) WHO, phylogenetic tree 20200112.6885385
Undiagnosed pneumonia: China (HU) (10): genome available, Hong Kong surveill. 20200111.6883998
Undiagnosed pneumonia: China (01): (HU) wildlife sales, market closed, RFI 20200102.6866757
2019
----
Undiagnosed pneumonia: China (HU): RFI 20191230.6864153
and other items in the archives
.................................................lk/uba/tw/may/ml
</body>
